Comparison of the effects of raloxifene and bazedoxifene on the health screening results of postmenopausal women

Comparison of the effects of raloxifene and bazedoxifene on the health screening results of postmenopausal women - Comparison of the effects of raloxifene and bazedoxifene on the health screening results of postmenopausal women

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009236

Enrollment

200

Registered

2012-11-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postmenopausal osteoporosis

Interventions

1-year treatment with 60 mg of raloxifene 1-year treatment with 20 mg of bazedoxifene

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: women diagnosed with postmenopausal osteoporosis

Exclusion criteria

Exclusion criteria: (1)venous thromboembolism (2)long-term immobility (3)antiphospholipid syndrome

Design outcomes

Primary

Measure	Time frame
the results of a health screening program, bone mineral density, bone turnover markers	—

Countries

Japan

Contacts

Public ContactMasakazu Terauchi

Tokyo Medical and Dental University Department of Women's Health

teragyne@tmd.ac.jp03-5803-4605

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026